False alarm: Postmenopausal hormone therapy and ovarian cancer

Climacteric

Volumn 10, Issue 6, 2007, Pages 466-470

  Shapiro, S ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Ovarian Cancer; Postmenopausal Hormone Therapy

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CLEAR CELL CARCINOMA; ENDOMETRIOID CARCINOMA; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HUMAN; HYSTERECTOMY; MENOPAUSAL SYNDROME; OVARY CANCER; OVARY CARCINOMA; OVARY TUMOR; PATHOLOGY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 36749089608     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701730539     Document Type: Review

References (8)

1. Million Women Study Collaborators. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet Online April 19, 2007
2. Prat HJ. Pathology of the Ovary. Philadelphia: Saunders, 2004
3. Million Women Study Collaborators. Breast cancer and hormone therapy in the Million Women Study. Lancet 2003;362:419-27
4. Kaufman DW, Kelly JP, Welch WR, et al. Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol 1989;130:1142-51
5. Weiss NS, Lyon JL, Krishnamurthy S, et al. Non-contraceptive estrogen use and the occurrence of ovarian cancer. JNCI 1982;115:714-19
6. Cramer DW, Hutchison GB, Welch WR, et al. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. JNCI 1983;71:711-16
7. Hartge P, Hoover R, McGowan L, et al. Ovarian cancer: incidence and case-control study. Am J Epidemiol 1988;127:990-8
8. Shapiro S. Commentary: Bias in the evaluation of low-magnitude associations: an empirical perspective. Am J Epidemiol 2000;151:939-45